Show simple item record

dc.contributor.authorJänne, P
dc.contributor.authorYang, J
dc.contributor.authorKim, D
dc.contributor.authorPlanchard, D
dc.contributor.authorOhe, Y
dc.contributor.authorRamalingam, S
dc.contributor.authorAhn, M
dc.contributor.authorKim, S
dc.contributor.authorSu, W
dc.contributor.authorHorn, L
dc.contributor.authorHaggstrom, D
dc.contributor.authorFelip, E
dc.contributor.authorKim, J
dc.contributor.authorFrewer, P
dc.contributor.authorCantarini, M
dc.contributor.authorBrown, K
dc.contributor.authorDickinson, P
dc.contributor.authorGhiorghiu, S
dc.contributor.authorRanson, Malcolm R
dc.date.accessioned2015-05-19T14:15:50Zen
dc.date.available2015-05-19T14:15:50Zen
dc.date.issued2015-04-30en
dc.identifier.citationAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. 2015, 372 (18):1689-99 N Engl J Meden
dc.identifier.issn1533-4406en
dc.identifier.pmid25923549en
dc.identifier.doi10.1056/NEJMoa1411817en
dc.identifier.urihttp://hdl.handle.net/10541/554171en
dc.description.abstractThe EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer). In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.
dc.language.isoenen
dc.rightsArchived with thanks to The New England journal of medicineen
dc.subject.meshAcrylamidesen
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshAniline Compoundsen
dc.subject.meshAntineoplastic Agentsen
dc.subject.meshCarcinoma, Non-Small-Cell Lungen
dc.subject.meshDisease-Free Survivalen
dc.subject.meshDose-Response Relationship, Drugen
dc.subject.meshDrug Resistance, Neoplasmen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshLung Neoplasmsen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshMutationen
dc.subject.meshProtein Kinase Inhibitorsen
dc.subject.meshReceptor, Epidermal Growth Factoren
dc.titleAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentLowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Bostonen
dc.identifier.journalThe New England Journal of Medicineen
html.description.abstractThe EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer). In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.


This item appears in the following Collection(s)

Show simple item record